Molecular testing for cancer is a laboratory method that analyzes a sample of tumor tissue, blood, or other body fluid to look for specific changes in genes, proteins, or other molecules that drive cancer growth. The results help doctors choose treatments that target the exact biological features of your cancer, rather than relying solely on where the tumor is located or how it looks under a microscope. It’s become a routine part of cancer care for many tumor types, and in some cases, it’s the single most important factor in deciding which therapy you’ll receive.
What Molecular Testing Actually Looks For
Every cancer is fueled by changes at the molecular level. Some of these changes are mutations in genes that tell cells to grow out of control. Others are abnormal proteins sitting on the surface of cancer cells, or rearrangements where pieces of two genes fuse together and create a new signal that drives the tumor. Molecular testing identifies these specific alterations so your oncologist can match you with a drug designed to block them.
In breast cancer, for example, tumor cells are routinely tested for estrogen receptors, progesterone receptors, and a protein called HER2. These three biomarkers determine whether you’ll benefit from hormone-blocking therapies, HER2-targeted drugs, or other approaches. In lung cancer, testing looks for mutations in genes like EGFR, ALK, and ROS1, each of which can be targeted with specific medications. Similar panels exist for colorectal cancer, melanoma, ovarian cancer, and many others.
Somatic vs. Inherited Mutations
There are two fundamentally different types of molecular tests, and they answer different questions. Somatic testing examines the tumor itself, looking for mutations the cancer cells acquired as they grew. These mutations aren’t inherited and can’t be passed to your children, but they reveal the tumor’s vulnerabilities. Germline testing, by contrast, uses a blood or saliva sample to check for inherited gene changes (like BRCA1 or BRCA2 mutations) that increased your risk of developing cancer in the first place.
These two types of tests use different technologies and can’t reliably substitute for each other. Research from the University of Wisconsin found that 35% of inherited gene variants were missed when doctors relied only on tumor-based somatic testing. If your medical team suspects a hereditary cancer syndrome, they’ll typically order germline testing separately.
How the Tests Are Performed
Several laboratory techniques power molecular testing, and which one your doctor orders depends on what they’re looking for.
- Next-generation sequencing (NGS) reads hundreds of genes at once, building what researchers call a “mutational portrait” of your cancer. It can analyze DNA for specific mutations and RNA for gene fusions. NGS takes longer and costs more than simpler tests, but it catches a wider range of alterations in a single run.
- FISH (fluorescence in situ hybridization) uses fluorescent probes that bind to specific stretches of DNA inside cells, making gene rearrangements or extra copies of a gene visible under a microscope. It’s often used to confirm results from initial screening tests.
- PCR (polymerase chain reaction) amplifies small amounts of DNA so that specific known mutations can be detected with high sensitivity. It’s fast and reliable when doctors are looking for one or a few particular changes.
Single-Gene Tests vs. Comprehensive Panels
In the early days of molecular testing, labs checked for one gene at a time. If the first test came back negative, they’d move to the next, which consumed both tissue and time. Comprehensive genomic profiling (CGP) changed that approach by using a single panel to assess hundreds of genes simultaneously, covering all the major categories of alterations that drive cancer growth, including microsatellite instability and tumor mutational burden, two markers that help predict whether immunotherapy will work.
The practical difference is significant. One study found that multi-gene panel testing detected actionable mutations in 30% of patients, compared to 23% with single-gene testing. That translated directly into more patients receiving targeted therapies (21% vs. 19%) and, notably, more than double the rate of patients receiving immunotherapy (16% vs. 7%). For cancers where multiple potential targets exist, comprehensive panels have largely replaced the older one-at-a-time approach.
Tissue Biopsy vs. Liquid Biopsy
The traditional source material for molecular testing is a tissue biopsy, a small piece of the tumor removed by needle or surgery. Tissue remains the gold standard because it provides a concentrated sample of cancer cells, and pathologists can enrich the DNA by selecting areas with the highest tumor content under a microscope. The downside: tissue biopsies are invasive, carry a risk of complications (especially in organs like the lung), and sometimes don’t yield enough usable DNA for analysis.
Liquid biopsies offer an alternative. A simple blood draw captures fragments of tumor DNA circulating in the bloodstream. The procedure is far less invasive, and because the circulating DNA comes from tumors throughout the body, it can capture a broader picture of the cancer’s genetic makeup than a single biopsy site. This matters because tumors are genetically diverse: cells in one part of the tumor may carry different mutations than cells in another part.
Liquid biopsies are especially useful when a tissue sample isn’t available, when the tumor is in a hard-to-reach location, or when your oncologist wants to monitor how the cancer’s genetics change over time with repeated blood draws. Current guidelines position liquid biopsy as a complement or alternative to tissue testing when tissue availability is limited, not as a wholesale replacement.
How Results Shape Treatment Decisions
The core purpose of molecular testing is matching you with the therapy most likely to work. A study of 345 young patients with solid tumors found that 86% had at least one genetic alteration with potential to influence their care. Sixty-five percent had alterations that could be used to select a matched targeted therapy. Among the patients who received a targeted drug matched to their specific gene fusion or mutation, 24% achieved a measurable tumor response or lasting clinical benefit.
Beyond choosing targeted drugs, molecular results can clarify a diagnosis (confirming exactly which subtype of cancer you have), provide prognostic information (how aggressive the cancer is likely to be), and identify whether immunotherapy is a good fit based on markers like tumor mutational burden. In some cases, the results reveal an inherited mutation that has implications for your family members’ screening plans.
Cost and Timing
The cost of molecular testing ranges from under $100 for a simple single-gene test to more than $2,000 for comprehensive genomic profiling. Many insurance plans cover molecular testing when it’s used to guide treatment decisions for an established cancer diagnosis, though coverage varies. From the time your sample reaches the lab, results typically take anywhere from a few days to several weeks, depending on the complexity of the panel. Your oncologist can usually give you a specific timeline based on which test they’ve ordered.
Waiting for results can feel frustrating, especially when you’re eager to start treatment. In many cases, though, delaying treatment by a week or two to get molecular results leads to a better-matched therapy and avoids rounds of treatment unlikely to work for your specific tumor biology.